ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

ANRS 12392 Sanu Gundo

Not Applicable

Conditions: HIV Infections

Interventions: Other: Local community-based HIV care

First Posted Date: 2020-07-22

Last Posted Date: 2021-02-25

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 265

Registration Number: NCT04482010

Locations: 🇲🇱
ARCAD Santé PLUS mobile care unit for recruitment of participants (Kofoulatiè, Intervention site), Kofoulaté, Koulikoro, Mali
🇲🇱
ARCAD Santé PLUS mobile care unit for community-based HIV care and study follow-up (Kofoulatiè, intervention site), Kofoulaté, Koulikoro, Mali
🇲🇱
ARCAD Santé PLUS mobile care unit for recruitment of participants (Diassa, control site), Diassa, Sikasso, Mali

and more 1 locations

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

Phase 2

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
COVID-19
COVID-19 Drug Treatment

Interventions: Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet
Drug: Atorvastatin 20 Mg Oral Tablet
Drug: Telmisartan 40Mg Oral Tablet

First Posted Date: 2020-07-10

Last Posted Date: 2021-02-04

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 294

Registration Number: NCT04466241

Locations: 🇨🇮
Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire
🇨🇮
Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire

HUSH Restriction in HIV Infected Patients

Conditions: HIV Infections

Interventions: Other: Blood sampling

First Posted Date: 2019-11-21

Last Posted Date: 2021-12-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 50

Registration Number: NCT04172480

Locations: 🇫🇷
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
🇫🇷
Hôtel-Dieu, Paris, France
🇫🇷
Hôpital Necker, Paris, France

Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection

Recruiting

Conditions: Hepatitis B, Chronic
Hepatitis D, Chronic

First Posted Date: 2019-11-18

Last Posted Date: 2023-08-21

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 400

Registration Number: NCT04166266

Locations: 🇫🇷
Saint-Antoine Hospital, Paris, France
🇫🇷
CHU of Angers, Angers, France
🇫🇷
Pitié-Salpêtrière Hospital, Paris, France

and more 8 locations

Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

Phase 3

Recruiting

Conditions: Tuberculous Meningitis

Interventions: Drug: Placebo of aspirin
Drug: Aspirin
Drug: WHO TBM treatment
Drug: Intensified TBM treatment

First Posted Date: 2019-10-30

Last Posted Date: 2024-01-22

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 768

Registration Number: NCT04145258

Locations: 🇺🇬
Mbarara Regional Reference Hospital, Mbarara, Uganda
🇺🇬
Regional Reference Hospital of Kabale, Mbarara, Uganda
🇨🇮
Treichville University Hospital, Abidjan, Côte D'Ivoire

and more 10 locations

Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina Faso

Conditions: Hepatitis C Virus Infection, Past or Present
Chronic Hepatitis c

First Posted Date: 2019-10-23

Last Posted Date: 2021-04-19

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 3300

Registration Number: NCT04136405

Locations: 🇧🇫
Région du Sud-Ouest, Gaoua, Burkina Faso

Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone

Not Applicable

Completed

Conditions: HIV-1 Infection

First Posted Date: 2019-10-21

Last Posted Date: 2023-08-07

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 20

Registration Number: NCT04133012

A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)

Phase 2

Completed

Conditions: HIV-1-infection

Interventions: Biological: Placebo vaccine and placebo infusion
Biological: Placebo vaccine and vedolizumab infusion (Entyvio)
Biological: Vaccine and vedolizumab (Entyvio)

First Posted Date: 2019-10-09

Last Posted Date: 2023-08-04

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 2

Registration Number: NCT04120415

Locations: 🇬🇧
St Stephens Centre, Chelsea & Westminster Hospital, London, United Kingdom
🇫🇷
Hotel Dieu, Paris, France
🇫🇷
Service Immunologie clinique et maladies infectieuses, Hôpital Henri Mondor, Paris, Creteil, France

and more 1 locations

Reducing Antiretroviral Treatments

Phase 3

Conditions: HIV-1-infection

Interventions: Drug: Antiretroviral

First Posted Date: 2019-08-09

Last Posted Date: 2021-08-09

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 360

Registration Number: NCT04051970

Locations: 🇫🇷
Hôpital la Salpêtrière, Paris, France

HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)

Conditions: HCV Infection
HIV Seropositivity

First Posted Date: 2019-08-05

Last Posted Date: 2019-10-22

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 1098

Registration Number: NCT04044586

Locations: 🇰🇭
University of Health Sciences, Phnom Penh, Cambodia

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy